Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Seaman, Ph.D.

Co-Author

This page shows the publications co-authored by Michael Seaman and Raphael Dolin.
Connection Strength

1.047
  1. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010 May 01; 201(9):1353-60.
    View in: PubMed
    Score: 0.436
  2. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010 May 01; 201(9):1361-70.
    View in: PubMed
    Score: 0.109
  3. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine. 2009 Mar 04; 27(10):1549-56.
    View in: PubMed
    Score: 0.100
  4. Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa606.
    View in: PubMed
    Score: 0.057
  5. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.048
  6. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
    View in: PubMed
    Score: 0.041
  7. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28.
    View in: PubMed
    Score: 0.037
  8. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014 Oct 01; 210(7):1052-61.
    View in: PubMed
    Score: 0.036
  9. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 Jun 15; 207(12):1888-97.
    View in: PubMed
    Score: 0.033
  10. Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine. 2012 Dec 17; 31(1):114-9.
    View in: PubMed
    Score: 0.032
  11. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):248-56.
    View in: PubMed
    Score: 0.032
  12. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):240-7.
    View in: PubMed
    Score: 0.032
  13. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18; 29(32):5203-9.
    View in: PubMed
    Score: 0.029
  14. The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine. 2009 Feb 18; 27(8):1154-65.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.